In GIST patients who had previously failed treatment with imatinib and sunitinib, a Phase 1b study (NCT01468688) using the PI3K inhibitor buparlisib in combination with Imatinib was conducted to assess the clinical profile of the combination (101). The gene discussed is PIK3CA; the disease is gastrointestinal stromal tumor.